Triheptanoin
- Generic Name
- Triheptanoin
- Brand Names
- Dojolvi
- Drug Type
- Small Molecule
- Chemical Formula
- C24H44O6
- CAS Number
- 620-67-7
- Unique Ingredient Identifier
- 2P6O7CFW5K
- Background
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.
Triheptanoin was granted FDA approval on 30 June 2020.
- Indication
Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).
- Associated Conditions
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Associated Therapies
- -
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.